Denali Therapeutics (DNLI) to Release Earnings on Thursday

Denali Therapeutics (NASDAQ:DNLI) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Denali Therapeutics to post earnings of ($0.5131) per share and revenue of $2.1540 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the firm earned ($0.78) EPS. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Denali Therapeutics Stock Up 4.4%

Shares of NASDAQ DNLI opened at $24.17 on Wednesday. Denali Therapeutics has a 1 year low of $12.58 and a 1 year high of $27.30. The firm’s 50-day moving average is $23.30 and its 200-day moving average is $21.17. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.84 billion, a PE ratio of -8.39 and a beta of 1.01.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Denali Therapeutics by 28.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. State Street Corp increased its holdings in Denali Therapeutics by 14.6% during the 4th quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after purchasing an additional 799,110 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Denali Therapeutics by 77.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after purchasing an additional 1,672,098 shares during the period. Alliancebernstein L.P. boosted its position in shares of Denali Therapeutics by 12.2% during the third quarter. Alliancebernstein L.P. now owns 3,520,414 shares of the company’s stock worth $51,116,000 after buying an additional 383,274 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Denali Therapeutics by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,374,303 shares of the company’s stock worth $39,198,000 after buying an additional 17,089 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on DNLI. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Morgan Stanley lifted their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Leerink Partners cut their target price on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. UBS Group restated a “buy” rating on shares of Denali Therapeutics in a report on Tuesday, June 16th. Finally, JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 price target for the company. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.17.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.